| Literature DB >> 21286275 |
Elisa Modonesi1, Manrico Balbi, Gian Paolo Bezante.
Abstract
Myocardial contrast echocardiography (MCE) is a relatively simple myocardial perfusion imaging technique which should be used in different clinical settings. The ability of MCE to provide a comprehensive assessment of cardiac structure, function, and perfusion is likely to make it the technique of choice for non-invasive cardiac imaging.Contrast agents are encapsulated microbubbles (MB) filled with either air or high-molecular-weight gas. They are innocuous, biologically inert and when administered intravasculary, the sound backscatter from the blood poll is enhanced because MB have the enormous reflective ability due to a large acoustic impedance mismatch between the bubble gas and surrounding blood.MCE is an ideal imaging tool for the assessment of left heart contrast and the myocardial microcirculation. MCE detects contrast MB at the capillary level within the myocardium and, thus, has the potential to assess tissue viability and the duration of the contrast effect. MCE was equivalent to SPECT for the detection of CAD with a tendency toward higher sensitivity of MCE compared with SPECT in microvascular disease and CAD. MCE is also a bedside technique that can be used early in patients presenting with acute heart failure to rapidly assess LV function (regional and global) and perfusion (rest and stress).Entities:
Keywords: Contrast echocardiography; myocardial perfusion.
Year: 2010 PMID: 21286275 PMCID: PMC2845791 DOI: 10.2174/157340310790231653
Source DB: PubMed Journal: Curr Cardiol Rev ISSN: 1573-403X
Principal Parameters of MCE
| Definity | Optison | Sonovue | |
|---|---|---|---|
| Composition | Perflutren lipid microsphere | Perflutren protein-type A | Sulphur hexafluoride in form of MB |
| Company | Bristol-Myers Squibb | Amersham Health AS | Bracco Imaging |
| Shell composition | Lipid | Albumin | Lipid- no shell surfactant stabilized |
| Mean diameter (µm) | 1,1-3,3 | 3,0-4,5 | 2,5 |
| Range | % less than 10 µm is 98%; maximum diameter 20 µm | % less than 10 µm is 98%; maximum diameter 32 µm | % less than 11 µm 99%; maximum diameter 20 µm |
| Metabolism | Stable gas not metabolized. Phospholipid component are metabolized to free fatty acids. | Stable gas not metabolized. Albumin handled by the normal metabolic route. | Sulphur exafluoride dissolves in the blood and is subsequently exhaled. |
| Elimination | By lungs; not detectable in the blood or expider air after 10’ | By lungs; not detectable in the blood or expider air after 10’ | By lungs; not detectable in the blood or expider air after 15’ |
| Bolus | 10 mL/Kg iv bolus injection whitin 30-60sec, followed by 10mL of saline flush. | 0.5 mL iv. This may be repeated for further contrast enhancement. | 2 or 2.4 ml and might be repeated. Every injection should be followed by saline flush. |
| Infusion | 1,3 mL added to 50 mL saline; rate of infusion should be initiated at 4.0 mL/min, but titraded as necessary | The injection rate should not exceed 1 mL per second, followed by a saline flush. | at 50 to 70 mL/h with VueJect (BR-INF 100,Bracco Research SA) |
| Maximun dosage | Not exceed 10 mL/min. The maximum dose is either low bolus doses or one single iv infusion. | Not exceed 5.0 mL in any 10 minute period. The maximum total dose should not exceed 8.7 mL in any one patient study. | In a Phase I study doses up to 56 ml of SonoVue were administered to normal volunteers without serious adverse events being reported. |
Contrast Specific Imaging Methods for Assessment of Myocardial Perfusion
| Harmonic B-mode | Harmonic power Doppler | Pulse invertion | Power pulse invertion | |
|---|---|---|---|---|
| Bubble-to-tissue sensivity | Moderate | Very good | Good | Very good |
| Off-line background subtraction needed | Yes | No | Yes | No |
| LV-myocardium delineation | Poor | Good | Moderate | Good |
| Wall motion artifacts | None | Can be severe | Moderate | Few |
| Real-time imaging | No | No | No | Yes |
Contraindications to the Use of Optison, Definity or Sonovue
| - Intra-arterial injection |
| - Right-to-left, bi-directional, or transient right- to-left cardiac shunts |
| - Worsening or clinically unstable congestive heart failure |
| - Acutemyocardial infarction or acute coronary syndromes |
| - Ventricular arrhythmias or high risk for arrhythmias due to QT prolongation |
| - Respiratory failure, as manifest by signs or symptoms of carbon dioxide retention or hypoxemia |
| - Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature |
| - Hypersensitivity to perflutren, blood, blood products, or albumin. |
Stress Protocol in Clinical Practice
| HR | BP | Scan | Regional and global function | ||
|---|---|---|---|---|---|
| Dobutamine | Increase | Increase systolic/diastolic BP | Difficult | Increase function and velocity of contraction compared with rest and usually with low dose; Greater decrease in ESV, marked increase in EF | Decrease function and velocity of contraction compared with low dose; may be less compared with rest; Often same as normal response, rarely, ischemia produces decreased EF; cavity dilatation rarely occurs |
| Vasodilator: Dipyridamole/Adenosine | Reduction | Decrease systolic/diastolic BP | Easier | Increase function compared with rest; Decrease in ESV, increase in EF | Decreased function compared with rest; Often same as normal response; occasionally, ischemia produces decreased EF; cavity dilatation rarely occours. |